The Bet Against Nvidia's AI Monopoly

That's not an incremental improvement; it's the difference between watching a movie and reading the screenplay one word per week.

Biotech firm Peptilogics has used Cerebras systems to optimize neural architecture search for peptide therapeutics, compressing discovery timelines from months to days. Researchers working on membrane proteins like GPCRs (a massive class of drug targets) have talked about finding ten new leads in a year versus the traditional pace of one drug per decade.

A Comeback Story, with Asterisks

This isn't Cerebras's first attempt at going public. The company originally filed an S-1 back in September 2024, only to pull it a year later in October 2025. The culprit? A UAE-based tech firm called G42, which at the time accounted for a staggering 87% of Cerebras's first-half 2024 revenue. That kind of customer concentration made investors nervous, and a CFIUS national security review complicated things further.

Cerebras spent the intervening months fixing both problems. G42's equity stake was restructured into non-voting shares, clearing the CFIUS review. And that massive OpenAI deal (covering up to 750 megawatts of compute through 2028) gave Cerebras exactly the customer diversification story it needed.

The financial trajectory helped too. First-half 2024 revenue hit $136.4 million, reflecting 245% year-over-year growth. Estimates for 2025 range from $600 million to $800 million as those big contracts ramp up.

Follow the Money

Cerebras has raised approximately $2.91 billion across eight funding rounds since its founding in 2016. The investor list reads like a who's who of growth-stage venture capital: Benchmark, Coatue, Tiger Global, Fidelity, Altimeter, and Alpha Wave Global have all written checks. AMD joined as a strategic investor in the most recent round, which is notable given that AMD is Nvidia's primary competitor in GPUs.

The February 2026 Series H alone brought in $1 billion at a $23 billion post-money valuation, led by Tiger Global. Secondary market shares have since traded between $102 and $107 per share, implying a valuation of $26 billion to $28 billion. That means the IPO pricing could actually represent a discount to where private shares are already changing hands.

The Elephant in the Room Is Named Jensen

Let's be honest about the challenge. Nvidia controls the AI chip market with an iron grip, and its CUDA software ecosystem creates switching costs that would make a cable company blush. Every major AI lab has spent years building their toolchains around Nvidia hardware. Cerebras is asking them to consider something fundamentally different.

The competitive field is crowded, too. Groq, SambaNova, and Graphcore are all chasing the same customers. Meanwhile, Microsoft, Google, and Amazon are designing their own custom AI silicon to reduce dependence on outside suppliers.

Public market investors will scrutinize Cerebras's gross margins, R&D spending, and whether wafer-scale technology can compete on performance per dollar against Nvidia's upcoming Blackwell architecture. The OpenAI deal provides revenue visibility, but it also raises a familiar question: how much of the company's future depends on a single (very large) customer?

What This Means for the IPO Market

Cerebras isn't going public in a vacuum. The AI chip IPO wave has been building for months, especially in Asia. Global AI investment is estimated to reach $2.53 trillion in 2026, up from $1.76 trillion in 2025.

If Cerebras prices well and trades up, it could open the floodgates for other AI infrastructure companies eyeing public markets. Some analysts have speculated about a coming "mega-wave" of tech IPOs from the likes of OpenAI, SpaceX, and Anthropic.

For biotech investors specifically, Cerebras's public debut is worth watching for a different reason. The company's technology sits at the intersection of AI and drug discovery, two fields that are converging faster than most people realize. If wafer-scale computing can genuinely compress molecular simulations from years to days, the downstream effects on how (and how fast) we develop new medicines could be enormous.

The aircraft carrier is heading for open water. Now we'll see if public market investors are ready to come aboard.

Merck's Secret Weapon for Life After Keytruda

Keytruda's patent cliff is approaching fast, and Merck just unveiled early data on a two-in-one cancer antibody that could help fill a $29.5 billion hole. The response rates are competitive, but the race is crowded and the clock is ticking.